Search

Your search keyword '"Manuli, C."' showing total 10 results
Start Over Author "Manuli, C."
10 results on '"Manuli, C."'

1. Prophylaxis of HBV-recurrence after liver transplantation in patients with HCC: Risk of HCC recurrence from a large, multicentre retrospective study from Italy

Author

Battistella, S., primary, Zanetto, A., additional, Turco, L., additional, Manuli, C., additional, Pasulo, L., additional, Giannelli, V., additional, Mameli, L., additional, Ferrarese, A., additional, Marenco, S., additional, Ferri, F., additional, Lenci, I., additional, Scandali, G., additional, Biolato, M., additional, Fornasiere, E., additional, Ponziani, F.R., additional, Baroni, G. Svegliati, additional, Giannini, E., additional, Toniutto, P., additional, Lanza, A. Galeota, additional, Rendina, M., additional, Donato, F., additional, Fagiuoli, S., additional, De Maria, N., additional, Morelli, M. Cristina, additional, Martini, Silvia, additional, Trapani, S., additional, Grossi, P., additional, Aghemo, A., additional, Russo, F.P., additional, and Burra, P., additional

Published
2023
Full Text
View/download PDF

10. Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients.

Author

Gambato M, Manuli C, Lynch EN, Battistella S, Germani G, Senzolo M, Zanetto A, Ferrarese A, Vitale A, Gringeri E, Cillo U, Burra P, and Russo FP

Subjects
Humans, Fibrosis, Retrospective Studies, Male, Female, Middle Aged, Survival Analysis, Hypertension, Portal therapy, Hepatitis C drug therapy, Hepatitis C therapy, Liver Transplantation, Antiviral Agents administration & dosage, Liver drug effects, Liver pathology, Liver physiology
Abstract

(1) Background: Little is known about the long-term impact of sustained virological response (SVR) on fibrosis progression and patient survival in liver transplantation (LT) recipients treated with direct-acting antivirals (DAAs). We investigated liver fibrosis evolution and patient survival in hepatitis C virus (HCV)-infected patients receiving DAAs after LT. (2) Methods: All consecutive HCV-infected patients treated with DAAs after LT between May 2014 and January 2019 were considered. The clinical and virological features were registered at the baseline and during the follow-up. The liver fibrosis was assessed by liver biopsy and/or transient elastography (TE) at the baseline and at least 1 year after the end of treatment (EoT). (3) Results: A total of 136 patients were included. The SVR12 was 78% after the first treatment and 96% after retreatment. After the SVR12, biochemical tests improved at the EoT and remained stable throughout the 3-year follow-up. Liver fibrosis improved after the SVR12 ( p < 0.001); nearly half of the patients with advanced liver fibrosis experienced an improvement of an F ≤ 2. The factors associated with lower survival in SVR12 patients were the baseline platelet count ( p = 0.04) and creatinine level ( p = 0.04). (4) Conclusions: The long-term follow-up data demonstrated that SVR12 was associated with an improvement in hepatic function, liver fibrosis, and post-LT survival, regardless of the baseline liver fibrosis. The presence of portal hypertension before the DAAs has an impact on patient survival, even after SVR12.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results